Figure S2. Mean plasma concentration–time curve of ascorbic acid after fixed-rate infusions at 0.6, 0.8, 1.0 g/min to cancer patients. After i.v. administration, the plasma concentrations of ascorbic acid rose gradually and peaked at 3 h. Cmax, and AUC values of ascorbic acid display dose-dependent increases. Ascorbic acid concentrations in the high-dose groups remained at 10–20 mmol/L for more than 4 h and showed no accumulation in the body during the administrations. (PDF 20 kb
Number of nuclei of HCT116 human colon carcinoma cells cultivated at 21 % or 3 % of oxygen in non-tr...
Figure S3. Aspirin and metformin synergize with fluvastatin to sensitize MCF10.AT1-R and MCF10.DCIS ...
Table S1. Results of univariate analysis of progression free survival in patients with mCRC. (DOCX 1...
Figure S1. Evaluation of the ascorbic acid dose proportionality in part 1 of the study. The mean AA ...
Table S1. Pharmacokinetic values. The volumes of distribution and clearance were similar to those pa...
Figure S1. (A) Representative semiprep HPLC chromatogram with upper UV and lower radio γ trace of 18...
Figure S2. (A) The relative transcription levels measured by RT-qPCR of TET1/2/3 in T24 cells treate...
Figure S1. (A) 5hmC level scoring by IHC staining (0–10%, 11–30%, 30–50%, and > 50%). (B) Dot blot a...
Supplementary main results on hazard ratios of cancer across quartiles of metabolite levels (Table S...
The graphs show the proliferation rate (BrdU; in % of control cells) for the seven different breast ...
Figure S1. Cholesterol loading and ovarian cancer cell viability. PA-1, OVCAR-3 and SKOV-3 ovarian c...
Table S1. The basic information of 8 colorectal cancer patients for TFAP2C mRNA and protein expressi...
Table S1. Antibodies used. Table S2. Relative levels of phosphorylated proteins associated with acti...
Pharmacokinetic properties of the seven FDA-approved statins. Absorption, distribution, metabolism, ...
Gemcitabine, CHK1i and ATRi IC50 values and combination indices (CI-ED50) in human lung cancer cell ...
Number of nuclei of HCT116 human colon carcinoma cells cultivated at 21 % or 3 % of oxygen in non-tr...
Figure S3. Aspirin and metformin synergize with fluvastatin to sensitize MCF10.AT1-R and MCF10.DCIS ...
Table S1. Results of univariate analysis of progression free survival in patients with mCRC. (DOCX 1...
Figure S1. Evaluation of the ascorbic acid dose proportionality in part 1 of the study. The mean AA ...
Table S1. Pharmacokinetic values. The volumes of distribution and clearance were similar to those pa...
Figure S1. (A) Representative semiprep HPLC chromatogram with upper UV and lower radio γ trace of 18...
Figure S2. (A) The relative transcription levels measured by RT-qPCR of TET1/2/3 in T24 cells treate...
Figure S1. (A) 5hmC level scoring by IHC staining (0–10%, 11–30%, 30–50%, and > 50%). (B) Dot blot a...
Supplementary main results on hazard ratios of cancer across quartiles of metabolite levels (Table S...
The graphs show the proliferation rate (BrdU; in % of control cells) for the seven different breast ...
Figure S1. Cholesterol loading and ovarian cancer cell viability. PA-1, OVCAR-3 and SKOV-3 ovarian c...
Table S1. The basic information of 8 colorectal cancer patients for TFAP2C mRNA and protein expressi...
Table S1. Antibodies used. Table S2. Relative levels of phosphorylated proteins associated with acti...
Pharmacokinetic properties of the seven FDA-approved statins. Absorption, distribution, metabolism, ...
Gemcitabine, CHK1i and ATRi IC50 values and combination indices (CI-ED50) in human lung cancer cell ...
Number of nuclei of HCT116 human colon carcinoma cells cultivated at 21 % or 3 % of oxygen in non-tr...
Figure S3. Aspirin and metformin synergize with fluvastatin to sensitize MCF10.AT1-R and MCF10.DCIS ...
Table S1. Results of univariate analysis of progression free survival in patients with mCRC. (DOCX 1...